Suven Pharmaceuticals Ltd
SUVENPHARSuven Pharmaceuticals Ltd
SUVENPHARPrice Chart
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
46.47 | 9.93 | 0.89% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.91 | 5.95 | 0.56% |
Forecast & Ratings
Detailed Forecastfrom 1 analyst
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Suven Pharmaceuticals is engaged in Contract Research and Manufacturing Services (CRAMS), Drug Discovery & Development Support Services (DDDSS), Drug Discovery & Research/Clinical Pipeline, and Formulation Development
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Zydus Lifesciences Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | TTM | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 378.43 | 900.12 | 1,077.69 | 1,453.71 | 1,386.69 | 1,224.04 | ||||||
Raw Materials | 124.52 | 240.24 | 310.32 | 459.46 | 430.08 | 668.63 | ||||||
Power & Fuel Cost | 18.06 | 38.24 | 44.20 | 59.55 | 73.93 | |||||||
Employee Cost | 29.63 | 65.10 | 76.23 | 100.48 | 110.51 | |||||||
Selling & Administrative Expenses | 16.23 | 44.76 | 44.96 | 53.18 | 55.25 | |||||||
Operating & Other expenses | 17.84 | 60.70 | 91.01 | 65.84 | 96.66 | |||||||
EBITDA | 172.15 | 451.08 | 510.97 | 715.20 | 620.26 | 555.41 | ||||||
Depreciation/Amortization | 11.50 | 23.51 | 31.64 | 39.10 | 47.73 | 49.14 | ||||||
PBIT | 160.65 | 427.57 | 479.33 | 676.10 | 572.53 | 506.27 | ||||||
Interest & Other Items | 2.79 | 23.07 | 11.67 | 8.53 | 12.81 | 5.23 | ||||||
PBT | 157.86 | 404.50 | 467.66 | 667.57 | 559.72 | 501.04 | ||||||
Taxes & Other Items | 48.59 | 87.51 | 105.34 | 213.78 | 148.44 | 130.14 | ||||||
Net Income | 109.27 | 316.99 | 362.32 | 453.79 | 411.28 | 370.90 | ||||||
EPS | — | 24.91 | 14.23 | 17.83 | 16.16 | 14.57 | ||||||
DPS | 0.00 | 2.50 | 2.00 | 5.00 | 6.00 | 0.00 | ||||||
Payout ratio | — | 0.10 | 0.14 | 0.28 | 0.37 | 0.00 |
Company Updates
Annual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Suven Pharmaceuticals Ltd | 41.91 | 9.93 | 0.89% |
Sun Pharmaceutical Industries Ltd | 45.89 | 6.56 | 0.71% |
Cipla Ltd | 43.13 | 5.10 | 0.57% |
Dr Reddy's Laboratories Ltd | 22.75 | 4.40 | 0.65% |
Price Comparison
Compare SUVENPHAR with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Mar 2023
Jun 2023
Sep 2023
Dec 2023
Shareholding History
Mutual Funds Holding Trend
Increased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has increased by 1.25%
Top 5 Mutual Funds holding Suven Pharmaceuticals Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
UTI Flexi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.7104% | Percentage of the fund’s portfolio invested in the stock 1.17% | Change in the portfolio weight of the stock over the last 3 months -0.13% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 41/66 (-8) |
DSP Healthcare Fund - Direct - Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.0222% | Percentage of the fund’s portfolio invested in the stock 7.60% | Change in the portfolio weight of the stock over the last 3 months -1.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 5/30 (-2) |
HSBC Small Cap Fund - Direct Plan - Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.8392% | Percentage of the fund’s portfolio invested in the stock 1.05% | Change in the portfolio weight of the stock over the last 3 months -0.12% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 25/106 (-1) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 9, 2022
Dividend/Share
₹1.00
Ex DateEx Date
Sep 9, 2022
Cash Dividend
Ex DateEx DateSep 9, 2022
Dividend/Share
₹5.00
Ex DateEx Date
Sep 9, 2022
Cash Dividend
Ex DateEx DateMay 13, 2022
Dividend/Share
₹1.00
Ex DateEx Date
May 13, 2022
Cash Dividend
Ex DateEx DateMay 13, 2022
Dividend/Share
₹1.00
Ex DateEx Date
May 13, 2022
Cash Dividend
Ex DateEx DateFeb 15, 2022
Dividend/Share
₹1.00
Ex DateEx Date
Feb 15, 2022
News & Opinions
Stocks to Watch: Paytm, Tata Group, Airtel, Vedanta, Suven Pharma, ONGC, and Others - News18
4 weeks ago•News18
Stocks To Watch: Adani Group, Paytm, Vedanta, Biocon, Dilip Buildcon, Auto Companies, Suven Pharma
4 weeks ago•Bloomberg Quint
Suven Pharma To Merge With Cohance Lifesciences
4 weeks ago•Bloomberg Quint
Suven Pharma Q2 results: Net profit declines 5.3% YoY to Rs 74.72 crore
4 months ago•Moneycontrol
Suven Pharma Gets New Board After Acquisition By Advent International
5 months ago•Bloomberg Quint
Cabinet okays FDI of up to Rs 9,589 crore for 76.1% stake in Hyderabad-based Suven Pharma - Times of India
6 months ago•Times of India
CCEA Clears Berhyanda’s Foreign Investment Proposal of Rs 9,589 Crore In Suven Pharma; Check Details - News18
6 months ago•News18
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant